Table 1.

In vivo efficacy using siRNA in pulmonary models

Target	Formulation	Route	Model	Reference
RSV-P, PIV-P	Saline or lipoplex	Intranasal	RSV infection; PIV infection	[8••]
SARS	D5W or surfactant	Intranasal	SARS infection	[9•]
Influenza A — NP, PA	PEI	Intravenous	Influenza virus infection	[10]
	Saline/oligofectamine	Intravenous hydrodynamic/intranasal	Influenza virus infection	[12]
HO-1	Saline	Intranasal	Hyperoxic acute lung injury	[15•]
KC, MIP-2, Fas	Saline	Intranasal	Septic acute lung injury	[17, 18]
Angiopoietin 2	Saline	Intranasal	Hyperoxic acute lung injury	[16•]
DDR1	Saline	Intranasal	Bleomycin-induced fibrosis	[31]
GFP	Chitosan NP	Intranasal	GFP transgenic	[24•]
Caveolin	Liposomes	Intravenous	Vascular permeability	[29]
IL-13	jetPEI	Intravenous	Airway hypersensitivity	[30]

Reports of positive in vivo efficacy in lung are listed along with formulation, route of administration and animal model utilized. All animal models were conducted in the mouse except for the SARS infection study which was performed in nonhuman primates. D5W, 5% dextrose; NP, nanoparticles; PEI, polyethylenimine; RSV, respiratory syncytial virus; PIV, parainfluenza virus; SARS, severe acute respiratory distress syndrome; GFP, green fluorescent protein.